Spyre Therapeutics, Inc. held its Annual Meeting on May 27, 2026, where stockholders approved the amended Employee Stock Purchase Plan, elected three directors, and ratified the appointment of KPMG as their accounting firm. Peter Harwin resigned, reducing the board size from eight to seven members.